NAT CANCER CENTER JAPAN has a total of 38 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), Taiwan and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are HOX THERAPEUTICS LTD, BERGSTEIN IVAN and COUNCIL QUEENSLAND INST MEDICAL RES.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | Taiwan | 7 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | United States | 5 | |
#5 | China | 4 | |
#6 | Canada | 2 | |
#7 | Singapore | 2 | |
#8 | Australia | 1 | |
#9 | Brazil | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Microbiology | |
#7 | Foods | |
#8 | Measuring microorganism processes | |
#9 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Matsumura Yasuhiro | 20 |
#2 | Yasunaga Masahiro | 14 |
#3 | Saijo Shinji | 12 |
#4 | Manabe Shino | 12 |
#5 | Hanaoka Shingo | 9 |
#6 | Nishikawa Hiroyoshi | 7 |
#7 | Fuchigami Hirobumi | 6 |
#8 | Matsuda Atsushi | 4 |
#9 | Fukuda Kyoko | 4 |
#10 | Kobayashi Tamiyo | 4 |
Publication | Filing date | Title |
---|---|---|
TW201922796A | Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same | |
TW201906820A | Carcinogenic inhibitor | |
EP3620471A1 | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
CN110494750A | The analysis system and program of the detection method of responsiveness regulatory T cells, the analytical equipment of responsiveness regulatory T cells, responsiveness regulatory T cells | |
WO2018159808A1 | Antibody-drug conjugate of anti-il-7r antibody, and pharmaceutical composition for treating cancer or inflammation and containing antibody-drug conjugate of anti-il-7r antibody and cytotoxic drug | |
EP3578650A1 | Novel t-cell receptor | |
WO2018131659A1 | Immunotherapeutic agent | |
WO2018034259A1 | Antibody binding to tmem132a, anticancer agent, and cancer test method | |
WO2017154868A1 | Anti-tmem-180 antibody, anticancer agent, and test method for cancer | |
CA3010808A1 | Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound |